Biosynth Carbosynth (Biosynth), a supplier of critical products and services to the life sciences industry, has acquired Pepscan, an expert provider of peptide-based products & services and portfolio company of the KKR Health Care Growth fund.
Biosynth’s ability to deliver chemical manufacturing services “from the first idea to the finished product” is now matched in peptides, with Pepscan’s expertise in both lead discovery & optimisation and GMP production combining with the capabilities of vivitide, the US peptide specialists, which joined Biosynth in March.
The two companies will form Biosynth’s new Peptide division, with broad capabilities and offering to the pharma & biotech, diagnostics and cosmetics industries, and their academic counterparts. Pepscan also brings proprietary technologies, like its patented CLIPS technology, which locks peptides into active conformations. CLIPS peptides are applied for lead discovery and optimisation, as well as in its epitope mapping platform.
